Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Triptolide was shown in experimental studies to inhibit the cyst formation and growth in
ADPKD models, while triptolide-containing formulation was revealed to potentially slow the
disease progression in several proteinuric ADPKD patients in our clinical practice. It
remains to be shown the effect of triptolide-containing formulation on total kidney volume
(TKV) enlargement and renal function protection in ADPKD patients.